Vandortuzumab vedotin

Cat. No. M24699

All AbMole products are for research use only, cannot be used for human consumption.

Synonym:

DSTP 3086S; RG 7450; MSTP2109A

Size	Price	Availability
100ug	USD 600 USD600	1-2 Weeks
1mg	USD 1200 USD1200	1-2 Weeks

Free Delivery on orders over USD 500 Bulk Inquiry?

Vandortuzumab vedotin (DSTP 3086S) is an antibody-drug-conjugate to target prostate cancer.

CAS Number	1471985-92-8
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.

Related Antibody-Drug Conjugates (ADCs) Products
Glembatumumab vedotin Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects.
Denintuzumab-MMAF Denintuzumab-MMAF is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells.
Enapotamab vedotin Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) with inhibitory potential against high AXL expressing non-small cell lung cancer (NSCLC).
Codrituzumab-MMAE (CHO) Codrituzumab-MMAE is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3).
Tisotumab Vedotin Tisotumab Vedotin is a tissue factor-directed antibody-drug conjugate (ADC) containing a tissue factor-specific fully human monoclonal antibody (TF-011) conjugated to monomethylmethane auristatin E (MMAE), which can be used in studies related to cervical cancer.

Catalog